Mavacamten HCM denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for mavacamten hcm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Issue a "Not FDA-Approved" Denial for Mavacamten — and Why It Is Appealable

Mavacamten holds full FDA approval for its labeled indication in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. A "not FDA-approved" denial in this context almost always reflects one of three administrative errors: the drug was coded incorrectly on the claim, Aetna's clinical policy has not been updated to reflect the current regulatory status, or the requested use was entered in a way that made it appear off-label. In any of these cases, the denial is factually incorrect and should be challenged immediately.

## Why This Denial Is Appealable

FDA approval is a matter of public record. If the prescription is for the approved indication, the insurer bears the burden of demonstrating that its "not FDA-approved" determination is accurate. An appeal that simply presents the FDA approval documentation alongside a prescriber letter confirming the on-label use will almost always succeed at internal or external review. Do not wait — these denials can often be resolved at the first internal level within days.

## Federal Appeal Framework

• Internal appeal: File immediately within the timeframe in the denial letter. Attach the FDA prescribing label and the prescriber's letter confirming on-label use. Request the specific basis for the not-FDA-approved determination.
• External review (ACA §2719): If the internal appeal fails (unusual in these cases), request independent external review within approximately four months of the final denial.
• ERISA §503: Employer-plan members may request all clinical criteria and documents Aetna relied on.
• Expedited review: Request if the denial is causing a dangerous gap in therapy.

## Documentation to Gather

• FDA prescribing label: Download the current FDA-approved full prescribing information for mavacamten. Highlight the approved indication and confirm it matches the diagnosis on the prescription.
• Diagnosis confirmation: Specialist records confirming symptomatic oHCM — the exact indication in the FDA label.
• Prescriber attestation: A brief letter from the treating cardiologist confirming the prescription is for the FDA-approved indication and is not off-label.
• Claim coding review: Ask your pharmacy or prescriber's office to verify that the NDC code and diagnosis code submitted on the claim are correct.

## Criteria-Mapping Structure

| Denial Basis | Rebuttal | |---|---| | Drug not FDA-approved | FDA approval confirmation — full prescribing label with indication | | Use is off-label | Prescriber letter confirming diagnosis matches FDA-approved indication exactly | | Coding error on claim | Corrected claim with accurate NDC and ICD code, if applicable |

This is one of the fastest-resolving denial types when the documentation is correct. If a corrected claim submission does not resolve it, escalate immediately to the formal internal appeal with the FDA label attached.